Edition:
United States

ImmunoGen Inc (IMGN.OQ)

IMGN.OQ on NASDAQ Stock Exchange Global Select Market

3.79USD
28 Mar 2017
Change (% chg)

-- (--)
Prev Close
$3.79
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
421,010
52-wk High
$9.77
52-wk Low
$1.51

Select another date:

Fri, Mar 24 2017

BRIEF-Biotest says Immunogen not to exercise late stage co-development option for US-market with Biotest's antibody-drug conjugate

* Immunogen has elected not to exercise its late stage co-development option for the us-market with Biotest's antibody-drug conjugate (BT-062) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Immunogen files for mixed shelf of up to $200 mln – SEC filing

* Immunogen Inc files for mixed shelf of up to $200 million – sec filing Source text for Eikon: Further company coverage:

BRIEF-Immunogen sees FY 2017 revenue $70 mln to $75 mln

* Immunogen reports recent progress and operating results for six-month period and quarter ended December 31, 2016

BRIEF-ImmunoGen announces first patient dosed in phase 3 study of mirvetuximab soravtansine in platinum-resistant ovarian cancer

* ImmunoGen announces first patient dosed in forward I Phase 3 study of mirvetuximab soravtansine in platinum-resistant ovarian cancer Source text for Eikon: Further company coverage:

BRIEF-Immunogen announces departure of Sandra Poole

* Poole, executive vice president, technical operations and commercial development, will leave company at end of January Source text for Eikon: Further company coverage:

BRIEF-Immunogen says cash balance at Dec 31, 2016 was about $160 mln

* On January 11, 2017, company said that its cash balance at December 31, 2016 (unaudited) was approximately $160 million - SEC filing Source text (http://bit.ly/2jI3xFH) Further company coverage:

BRIEF-Immunogen - Mirvetuximab soravtansine is entering a phase 3 trial, forward i, as a single agent treatment for platinum-resistant ovarian cancer

* Immunogen - Mirvetuximab soravtansine is entering a phase 3 trial, forward i, as a single agent treatment for platinum-resistant ovarian cancer

BRIEF-Immunogen CFO Johnston buys 10,000 shares of co's common stock on Nov 2

* Immunogen Inc CFO David Johnston reports open market purchase of 10,000 shares of co's common stock on Nov 2 at $1.70per share Source text: (http://bit.ly/2e5xpJI) Further company coverage:

BRIEF-Immunogen quarterly loss $0.51 per share

* Immunogen reports financial results for quarter ended September 30 and reviews business highlights

BRIEF-Immunogen: Will reduce workforce by 17 pct

* Company will reduce its workforce by 17 pct and seek to partner its non-core b-cell lymphoma programs

Select another date:

More From Around the Web